Mustang Bio, Inc. (MBIO)

The investment case here is structurally broken. The company has endured seven consecutive years of negative annual returns, culminating in a catastrophic 99.95% cumulative decline over the observation window. This is not merely a temporary downturn; the market has consistently reassessed the business quality downward for nearly a decade, evidenced by the relentless price erosion from thousands of dollars per share to sub-dollar levels. Fundamentally, the picture is dire: negative earnings, negative free cash flow, and negative returns on both assets and equity indicate a business that is currently destroying capital rather than generating it. While the current price trades at a discount to book value, this is likely a reflection of the severe impairment in the underlying asset quality and future prospects, not a margin of safety. There is no dividend to provide income, and the recent price action shows no signs of stabilization or recovery, hovering near multi-year lows. For a biotech firm in a pre-revenue stage with such a prolonged track record of failure, the risk of permanent capital loss is overwhelming, making this a clear avoidance.